TBH Global Asset Management LLC grew its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 21.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 42,765 shares of the company’s stock after purchasing an additional 7,647 shares during the period. Johnson & Johnson makes up about 1.4% of TBH Global Asset Management LLC’s portfolio, making the stock its 16th biggest position. TBH Global Asset Management LLC’s holdings in Johnson & Johnson were worth $6,628,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of the stock. DORCHESTER WEALTH MANAGEMENT Co lifted its stake in shares of Johnson & Johnson by 8.6% during the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after acquiring an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P lifted its stake in shares of Johnson & Johnson by 88.9% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after acquiring an additional 82,429 shares during the last quarter. AMI Investment Management Inc. lifted its stake in shares of Johnson & Johnson by 8.8% during the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after acquiring an additional 1,475 shares during the last quarter. Equitable Holdings Inc. lifted its stake in shares of Johnson & Johnson by 4.9% during the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after acquiring an additional 2,119 shares during the last quarter. Finally, USS Investment Management Ltd lifted its stake in shares of Johnson & Johnson by 2.4% during the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after acquiring an additional 20,528 shares during the last quarter. 67.57% of the stock is owned by institutional investors.
Insider Activity
In other news, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the transaction, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The disclosure for this sale can be found here. Insiders sold a total of 47,163 shares of company stock valued at $7,928,856 in the last quarter. 0.20% of the stock is currently owned by company insiders.
Johnson & Johnson Stock Up 0.9 %
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. The company had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The firm’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.59 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.75 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be issued a $1.19 dividend. The ex-dividend date is Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.74%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.
Analyst Ratings Changes
JNJ has been the topic of several research reports. StockNews.com initiated coverage on Johnson & Johnson in a report on Thursday. They set a “strong-buy” rating on the stock. Stifel Nicolaus raised their price objective on Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Citigroup initiated coverage on Johnson & Johnson in a report on Tuesday, May 30th. They set a “buy” rating and a $185.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, July 31st. Finally, Atlantic Securities lifted their price target on Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a report on Friday, August 4th. Eight research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $171.80.
Read Our Latest Stock Report on JNJ
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- 3 Monster Growth Stocks to Buy Now
- 7 Best Bear Market ETFs to Battle a Market Decline
- Stock Analyst Ratings and Canadian Analyst Ratings
- How to Invest in Wheat: Is it a Hedge Against Inflation?
- Technology Stocks Explained: Here’s What to Know About Tech
- Walmart Wins the Retail Wars: Target is Losing Ground
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
